Quotient Clinical, an early phase drug development services provider, has acquired SeaView Research, expanding its operations into the U.S. SeaView’s clinical pharmacology business has 160 employees across two clinical pharmacology units located in Miami and Jacksonville, FL, and a combined bed capacity of 320. Each of the facilities is capable of undertaking complex clinical research studies including first-in-human investigations. 
 
Quotient’s Translational Pharmaceutics platform integrates clinical testing with formulation development and real-time GMP manufacturing. This approach aims to reduce clinical development timelines and associated costs.
 
Mark Egerton, chief executive officer, Quotient, said, “Establishing an operational footprint in the US is an important milestone in the development of our business. We can now offer our customers the option to undertake their early phase clinical research either in the UK or the USA, and the acquisition of SeaView is a key component of our plan to replicate our Translational Pharmaceutics platform in the U.S.”
  
Stuart Harris and Celina Alvarez, co-founders of SeaView, said, “We are excited to join forces with Quotient and are looking forward to working together to continue growing the business. The combination of the Quotient and SeaView businesses enables us to deliver full service support to our customers, and the market potential for Translational Pharmaceutics in the U.S. is significant.”